PD-L1 expression does not predict BCG-failure in a large cohort of high-risk non-muscle invasive bladder cancer patients

Autor: F.C. De Jong, R.F. Hoedemaeker, A.M. Van Der Made, V. Kvikstad, T.P.P. Van Den Bosch, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon

Publikováno v: European Urology Open Science, Vol 19, Iss , Pp e1013- (2020)

Externí odkaz: https://doaj.org/article/cb0e17bd171a4786aad2fc5de63c50d0

Pathological T1 substaging corresponds with BCG-failure and improves the current EAU risk stratification for non-muscle invasive bladder cancer patients

Autor: F.C. De Jong, R. Hoedemaeker, V. Kvikstad, J.T. Mensink, E.R. Boevé, D.K.E. Van Der Schoot, J.L. Boormans, E.C. Zwarthoff, T.C.M. Zuiverloon

Publikováno v: European Urology Open Science, Vol 19, Iss , Pp e1419- (2020)

Externí odkaz: https://doaj.org/article/95eba4714a5340bd827386ee659e0b05

GATA2 methylation and FGFR3 mutation predict progression in BCG-treated high-risk non-muscle-invasive bladder cancer

Autor: M. Olislagers, F.C. De Jong, V.M.J. Van Etten, T.W. Kan, T.C.M. Zuiverloon

Publikováno v: European Urology. 83:S405-S406

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::410bbfd2e7b895443ca2af3c50456cfe
https://doi.org/10.1016/s0302-2838(23)00330-5

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III

Autor: M.J. Reike, M.A. Ingersoll, D.C. Müller, T.C.M. Zuiverloon, T. Strandgaard, A.M. Kamat, S.B. Williams, R. Seiler, T. Todenhöfer, L. Dyrskjøt, R. Nawroth, P. Goebell, B. Schmitz-Dräger, J.P. Sfakianos, J. Meeks, A. Horowitz, P.C. Black

Publikováno v: Urologic Oncology: Seminars and Original Investigations
Urologic Oncology: Seminars and Original Investigations, 2023, 41 (5), pp.211-218. ⟨10.1016/j.urolonc.2022.09.012⟩

International audience; Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9a3de23738f1fdb748fd71fea881c2
https://pubmed.ncbi.nlm.nih.gov/36266219